Senthil Damodaran, MD, PhD.

Peer-Reviewed Articles

1. Zhao M, Wang B, Evans KW, Scott S, Yuca E, Raso G, Rizvi YQ, Zheng X, Li D, Li J, Liang H, Akcakanat A, Brockman M, Damodaran S, Meric-Bernstam F. Inhibitors of IAP/XIAP enhance activity of sacituzumab govitecan. J Natl Cancer Inst, 2026. e-Pub 2026. PMID: 42569934.
2. Raghavendra AS, Qiao W, Shen Y, Damodaran S, Hunt KK, Tripathy D. Real-world study of treatment patterns and outcomes in patients with HR+ breast cancer after progression on CDK4/6 inhibitor therapy. Lancet Reg Health Am 59:101482, 2026. e-Pub 2026. PMID: 42125730.
3. Seth S, Yam C, Huo L, Lim B, Rinkenbaugh AL, White JB, Ravenberg EE, Song X, Litton JK, Tripathy D, Valero V, Damodaran S, Arun B, Ueno NT, Lucci A, Thompson AM, Mittendorf EA, Rauch GM, Adrada B, Candelaria RP, Ding Q, Powell RT, Abuhadra NK, Zhang J, Futreal A, Draetta GF, Piwnica-Worms H, Symmans WF, Chang JT, Moulder SL. The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancer. Breast Cancer Res, 2026. e-Pub 2026. PMID: 42093035.
4. Singareeka Raghavendra, A, Liu, D, Pasyar, S, Damodaran, S, Shen, Y, Mouabbi, JA, Barcenas, CH, Tripathy, D. Prevalence of HER2-low status and outcomes in early-stage HER2-negative breast cancer. NPJ Breast Cancer 12(1), 2026. e-Pub 2026. PMID: 41663417.
5. Wang J, Minussi DC, Davis A, Wei R, Ye H, Sei E, Schalck A, Yan Y, Wu HJ, Bai S, Peng C, Hu M, Casasent A, Contreras A, Chen H, Hui D, Damodaran S, Edgerton ME, Kopetz S, Lim B, Navin N. Delineating the copy-number substructure of metastatic tumors with CopyKit. Molecular Cell 86(2):407-422.e6, 2026. e-Pub 2026. PMID: 41534520.
6. Singareeka Raghavendra, A, Liu, D, Damodaran, S, Pasyar, S, Shen, Y, Mouabbi, JA, Barcenas, CH, Hunt, KK, Tripathy, D. Prevalence and Outcomes of HER2-Low Versus HER2-0 Status in Patients with Metastatic Breast Cancer. Cancers 18(2), 2026. e-Pub 2026. PMID: 41595172.
7. Luo, L, Yang, P, Mastoraki, S, Rao, X, Wang, Y, Kettner, NM, Singareeka Raghavendra, A, Tripathy, D, Damodaran, S, Hunt, KK, Wang, J, Li, Z, Keyomarsi, K. Single-cell RNA sequencing identifies molecular biomarkers predicting late progression to CDK4/6 inhibition in patients with HR+/HER2- metastatic breast cancer. Molecular cancer 24(1), 2025. e-Pub 2025. PMID: 39955556.
8. Kettner, NM, Bui, T, Navarro-Yepes, J, Ghotbaldini, S, Quintela, B, Luo, CK, Lam, N, Rao, X, Singareeka Raghavendra, A, Wang, Y, Azizian, NG, Kris Eckols, T, Kasembeli, MM, Evans, KW, Yi, M, Wingate, H, Wang, J, Sahin, AA, Meric-Bernstam, F, Hunt, KK, Damodaran, S, Tweardy, D, Tripathy, D, Keyomarsi, K. IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer. NPJ Precision Oncology 9(1), 2025. e-Pub 2025. PMID: 40715551.
9. Nelson, BE, Janku, F, Fu, S, Ileana Dumbrava, EE, Hong, DS, Karp, DD, Naing, A, Rodon Ahnert, J, Tsimberidou, AM, Murthy, R, Sheth, RA, Amaria, RN, Conley, AP, Damodaran, S, Raghav, KS, Carapanceanu, N, Singh, MP, Carapanceanu, V, Pezeshki, A, Leontovich, A, Kreider, B, Tung, D, Varterasian, M, Khazaie, K, Piha-Paul, SA. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. Clinical Cancer Research 31(18):3864-3875, 2025. e-Pub 2025. PMID: 40643985.
10. Goetz MP, Wander SA, Bachelot T, de Nonneville A, Gal-Yam EN, Sammons SL, Shen S, Twelves C, Boruta G, Portman DJ, Damodaran S. ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer. Future Oncol 21(11):1317-1324, 2025. e-Pub 2025. PMID: 40222048.
11. Raghavendra AS, Bassett R Jr, Damodaran S, Barcenas CH, Mouabbi JA, Layman R, Tripathy D. Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma. JAMA Netw Open 8(4):e251888, 2025. e-Pub 2025. PMID: 40293750.
12. Piha-Paul SA, Tseng C, Tran HT, Naing A, Dumbrava EE, Karp DD, Rodon J, Yap TA, Raghav KP, Damodaran S, Le X, Soliman PT, Lim J, Meric-Bernstam F. Phase I trial of the combination of the pan-ErbB inhibitor neratinib and mTOR inhibitor everolimus in advanced cancer patients with ErbB family gene alterations. ESMO Open 10(2):104136, 2025. e-Pub 2025. PMID: 39908697.
13. Raghavendra AS, Kettner NM, Kwiatkowski D, Damodaran S, Wang Y, Ramirez D, Gombos DS, Hunt KK, Shen Y, Keyomarsi K, Tripathy D. Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2- breast cancer. NPJ Breast Cancer 11(1):7, 2025. e-Pub 2025. PMID: 39865083.
14. Gouda MA, Gonugunta A, Dumbrava EE, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Mouabbi J, Tripathy D, Sahin AA, Chen H, Meric-Bernstam F. Human Epidermal Growth Factor Receptor 2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. Clin Cancer Res 31(7):1268-1274, 2025. e-Pub 2025. PMID: 39841861.
15. Lei JT, Dobrolecki LE, Huang C, Srinivasan RR, Vasaikar SV, Lewis AN, Sallas C, Zhao N, Cao J, Landua JD, Moon CI, Liao Y, Hilsenbeck SG, Osborne CK, Rimawi MF, Ellis MJ, Petrosyan V, Wen B, Li K, Saltzman AB, Jain A, Malovannaya A, Wulf GM, Marangoni E, Li S, Kraushaar DC, Wang T, Damodaran S, Zheng X, Meric-Bernstam F, Echeverria GV, Anurag M, Chen X, Welm BE, Welm AL, Zhang B, Lewis MT. Patient-Derived Xenografts of Triple-Negative Breast Cancer Enable Deconvolution and Prediction of Chemotherapy Responses. bioRxiv, 2025. e-Pub 2025. PMID: 39713418.
16. Lynch MM, Hermida-Viveiros P, Stencel S, Knott H, Al-Maryati R, Obeidin F, Alexiev BA, Abbinanti S, Damodaran S, Agulnik M, Pollack SM. Durable disease regression with copanlisib treatment in PI3K-mutated metastasizing ameloblastoma: A case report. Rare Tumors 17:20363613241309961, 2025. e-Pub 2025. PMID: 39790867.
17. Meric-Bernstam F, Yuca E, Evans KW, Zhao M, Maejima T, Karibe T, Raso MG, Tang X, Zheng X, Rizvi YQ, Akcakanat A, Scott SS, Wang B, Byers LA, Tripathy D, Okajima D, Damodaran S. Anti-tumor activity and biomarker analysis for TROP2-antibody drug conjugate Datopotamab deruxtecan in patient-derived breast cancer xenograft models. Clin Cancer Res 31(3):573-587, 2024. e-Pub 2024. PMID: 39585341.
18. Yam C, Patel M, Hill HA, Sun R, Bassett RL Jr, Kong E, Damodaran S, Koenig KB, Abouharb S, Saleem S, Bisen AK, Murthy RK, Ramirez DL, Rauch GM, Adrada BE, Candelaria RP, Wang X, Mittendorf EA, Thompson AM, White JB, Ravenberg EE, Clayborn AR, Ding QQ, Booser DJ, Oke O, Brewster AM, Hortobagyi GN, Ibrahim NK, Litton JK, Valero V, Arun BK, Tripathy D, Chang JT, Chen K, Korkut A, Moulder SL, Huo L, Lim B, Ueno NT. Targeting the Epidermal Growth Factor Receptor Pathway in Chemotherapy-Resistant Triple-Negative Breast Cancer: A Phase II Study. Cancer Res Commun 4(10):2823-2834, 2024. e-Pub 2024. PMID: 39356138.
19. Bardia A, Krop IE, Kogawa T, Juric D, Tolcher AW, Hamilton EP, Mukohara T, Lisberg A, Shimizu T, Spira AI, Tsurutani J, Damodaran S, Papadopoulos KP, Greenberg J, Kobayashi F, Zebger-Gong H, Wong R, Kawasaki Y, Nakamura T, Meric-Bernstam F. Datopotamab Deruxtecan in Advanced or Metastatic HR+/HER2- and Triple-Negative Breast Cancer: Results From the Phase I TROPION-PanTumor01 Study. J Clin Oncol 42(19):JCO2301909, 2024. e-Pub 2024. PMID: 38652877.
20. Lim B, Seth S, Yam C, Huo L, Fujii T, Lee J, Bassett Jr, R, Nasser S, Ravenberg L, White JB, Clayborn A, Guerra G, Litton J, Damodaran S, Layman RM, Valero V, Tripathy D, Lewis MT, Dobrolecki LE, Lei JT, Candelaria RP, Arun BK, Rauch GM, Zhao L, Zhang J, Ding Q, Symmans WF, Chang J, Thompson A, Moulder S, Ueno NT. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC. Cell Reports Medicine 5(6), 2024. e-Pub 2024. PMID: 38838676.
21. Basho RK, Zhao L, White JB, Huo L, Bassett RL, Mittendorf EA, Thompson A, Litton JK, Ueno N, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada BE, Santiago L, Ravenberg E, Seth S, Yam C, Moulder SL, Damodaran S. Comprehensive analysis identifies variability in PI3K pathway alterations in triple-negative breast cancer subtypes. JCO Precis Oncol 8:e2300124, 2024. e-Pub 2024. PMID: 38484209.
22. Goetz MP, Bagegni NA, Batist G, Brufsky AM, Cristofanilli M, Damodaran S, Daniel B, Fleming GF, Gradishar WJ, Graff SL, Grosse Perdekamp MT, Hamilton E, Lavasani S, Moreno-Aspitia A, O'Connor T, Pluard T, Rugo H, Sammons S, Schwartzberg L, Stover DG, Vidal GA, Wang G, Warner E, Yerushalmi R, Plourde PV, Portman DJ, Nili Gal-Yam E. Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial. Annals of Oncology 34(12):1141-1151, 2023. e-Pub 2023. PMID: 38072514.
23. Damodaran S, Sullivan CCO, Elkhanany A, Anderson IC, Barve M, Blau S, Cherian M, Peguero A, Goetz MP, Plourde PV, Portman DJ, Moore HCF. Open-label, phase 2, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after progression on prior therapies: ELAINE 2. Annals of Oncology 34(12):1131-1140, 2023. e-Pub 2023. PMID: 38072513.
24. Saridogan T, Akcakanat A, Zhao M, Evans KW, Yuca E, Scott S, Kirby BP, Zheng X, Ha MJ, Chen H, Ng PKS, DiPeri TP, Mills GB, Rodon Ahnert J, Damodaran S, Meric-Bernstam F. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor inhibitor, in FGFR-altered breast cancer. Sci Rep 13(1):20223, 2023. e-Pub 2023. PMID: 37980453.
25. Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res 83(19):3264-3283, 2023. e-Pub 2023. PMID: 37384539.
26. Zhao M, DiPeri TP, Raso MG, Zheng X, Rizvi YQ, Evans KW, Yang F, Akcakanat A, Roberto Estecio M, Tripathy D, Dumbrava EE, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 and SLFN11 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. NPJ Breast Cancer 9(1):66, 2023. e-Pub 2023. PMID: 37567892.
27. Nelson BE, Saleem S, Damodaran S, Somaiah N, Piha-Paul S, Moore JA, Yilmaz B, Ogbonna D, Karp DD, Dumbrava E, Tsimberidou AM, Hong DS, Rodon Ahnert J, Milton DR, Zheng X, Booser DJ, Ibrahim NK, Conley AP, Bhosale P, Rojas Hernandez CM, Tripathy D, Naing A, Meric-Bernstam F. Phase 1b study of combined selinexor and eribulin for the treatment of advanced solid tumors and triple-negative breast cancer. Cancer 129(14):2201-2213, 2023. e-Pub 2023. PMID: 37016732.
28. Abuhadra N, Sun R, Yam C, Rauch GM, Ding Q, Lim B, Thompson AM, Mittendorf EA, Adrada BE, Damodaran S, Virani K, White J, Ravenberg E, Sun J, Choi J, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin A, Valero V, Symmans WF, Litton JK, Tripathy D, Moulder S, Huo L. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel) 15(13), 2023. e-Pub 2023. PMID: 37444385.
29. Yam C, Mittendorf EA, Garber HR, Sun R, Damodaran S, Murthy RK, Ramirez D, Karuturi M, Layman RM, Ibrahim N, Rauch GM, Adrada BE, Candelaria RP, White JB, Ravenberg E, Clayborn A, Ding QQ, Symmans WF, Prabhakaran S, Thompson AM, Valero V, Tripathy D, Huo L, Moulder SL, Litton JK. A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer. Breast Cancer Res Treat 199(3):457-469, 2023. e-Pub 2023. PMID: 37061619.
30. Abuhadra N, Sun R, Bassett RL, Huo L, Chang JT, Teshome M, Clayborn AR, White JB, Ravenberg EE, Adrada BE, Candelaria RP, Yang W, Ding Q, Symmans WF, Arun B, Damodaran S, Koenig KB, Layman RM, Lim B, Litton JK, Thompson A, Ueno NT, Piwnica-Worms H, Hortobagyi GN, Valero V, Tripathy D, Rauch GM, Moulder S, Yam C. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs 41(3):391-401, 2023. e-Pub 2023. PMID: 37043123.
31. Blau S, Peguero JA, Moore HCF, Anderson IC, Barve MA, Cherian MA, Elkhanany A, O'Sullivan CC, Moreno-Aspitia A, Plourde P, Gleich LL, Riesen K, Ezzati R, Degele M, Shulman M, Stempf SD, Sachse L, Iyer AA, Damodaran S, Cooney MM. Operational Metrics for the ELAINE 2 Study Combining a Traditional Approach With a Just-in-TIME Model. JCO Clin Cancer Inform 7, 2023. e-Pub 2023. PMID: 37352479.
32. Chen H, Ding Q, Khazai L, Zhao L, Damodaran S, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Lim B, Thompson AM, Mittendorf EA, Adrada B, Virani K, White JB, Ravenberg E, Song X, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Routbort MJ, Sahin A, Valero V, Symmans WF, Tripathy D, Wang WL, Moulder S, Huo L. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol 15:17588359231189422, 2023. e-Pub 2023. PMID: 37547448.
33. Irajizad E, Wu R, Vykoukai J, Murage E, Spencer R, Dennison JB, Moulder S, Ravenbert E, Lim B, Liitton J, Tripathy D, Valero V, Damodaran S, Rauch GM, Adrada B, Candelaria R White JB, Brewster A, Arun B, Long JP, Do KA, Hanash S, Fahrmann JF. Application of artificial intelligence to plasma metabolomics profiles to predict response to neoadjuvant chemotherapy in triple-negative breast cancer. Frontiers in Artificial Intelligence 5(876100), 2022. e-Pub 2022. PMID: 36034598.
34. Yam C, Abuhadra N, Sun R, Adrada BE, Ding QQ, White JB, Ravenberg EE, Clayborn AR, Valero V, Tripathy D, Damodaran S, Arun BK, Litton JK, Ueno NT, Murthy RK, Lim B, Baez L, Li X, Buzdar AU, Hortobagyi GN, Thompson AM, Mittendorf EA, Rauch GM, Candelaria RP, Huo L, Moulder SL, Chang JT. Molecular characterization and prospective evaluation of pathological response and outcomes with neoadjuvant therapy in metaplastic triple-negative breast cancer. Clin Cancer Res 28(13):2878-2889, 2022. e-Pub 2022. PMID: 35507014.
35. Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting-a large institutional study. Int J Cancer 150(12):2025-2037, 2022. e-Pub 2022. PMID: 35133007.
36. Andre F, Ismaila N, Allison KH, Barlow WE, Collyar DE, Damodaran S, Henry NL, Jhaveri K, Kalinsky K, Kuderer NM, Litvak A, Mayer EL, Pusztai L, Raab R, Wolff AC, Stearns V. Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol 40(16):JCO2200069, 2022. e-Pub 2022. PMID: 35439025.
37. Damodaran S, Zhao F, Deming DA, Mitchell EP, Wright JJ, Gray RJ, Wang V, McShane LM, Rubinstein LV, Patton DR, Williams PM, Hamilton SR, Suga JM, Conley BA, Arteaga CL, Harris LN, O'Dwyer PJ, Chen AP, Flaherty KT. Phase II Study of Copanlisib in Patients With Tumors With PIK3CA Mutations: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1F. Journal of Clinical Oncology 40(14):1552-1561, 2022. e-Pub 2022. PMID: 35133871.
38. Abuhadra N, Sun R, Litton JK, Rauch GM, Yam C, Chang JT, Seth S, Bassett R, Lim B, Thompson AM, Mittendorf E, Adrada BE, Damodaran S, White J, Ravenberg E, Candelaria R, Arun B, Ueno NT, Santiago L, Saleem S, Abouharb S, Murthy RK, Ibrahim N, Sahin AA, Valero V, Symmans WF, Tripathy D, Moulder S, Huo L. Prognostic Impact of High Baseline Stromal Tumor Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel) 14(5), 2022. e-Pub 2022. PMID: 35267631.
39. Yam C, Yen EY, Chang JT, Bassett RL, Al-Atrash G, Garber H, Huo L, Yang F, Philips AV, Ding QQ, Lim B, Ueno NT, Kannan K, Sun X, Sun B, Parra ER, Symmans WF, White JB, Ravenberg E, Seth S, Guerriero JL, Rauch GM, Damodaran S, Litton JK, Wargo JA, Hortobagyi GN, Futreal A, Wistuba II, Sun R, Moulder-Thompson S, Mittendorf EA. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res 27(19):5365-5375, 2021. e-Pub 2021. PMID: 34253579.
40. Musall BC, Abdelhafez AH, Adrada BE, Candelaria RP, Mohamed RMM, Boge M, Le-Petross H, Arribas E, Lane DL, Spak DA, Leung JWT, Hwang KP, Son JB, Elshafeey NA, Mahmoud HS, Wei P, Sun J, Zhang S, White JB, Ravenberg EE, Litton JK, Damodaran S, Thompson AM, Moulder SL, Yang WT, Pagel MD, Rauch GM, Ma J. Functional Tumor Volume by Fast Dynamic Contrast-Enhanced MRI for Predicting Neoadjuvant Systemic Therapy Response in Triple-Negative Breast Cancer. J Magn Reson Imaging 54(1):251-260, 2021. e-Pub 2021. PMID: 33586845.
41. Akcakanat A, Zheng X, Cruz Pico CX, Kim TB, Chen K, Korkut A, Sahin A, Holla V, Tarco E, Singh G, Damodaran S, Mills GB, Gonzalez-Angulo AM, Meric-Bernstam F. Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer. Clin Cancer Res 27(11):3243-3252, 2021. e-Pub 2021. PMID: 33782032.
42. Yam C, Rauch GM, Rahman T, Karuturi M, Ravenberg E, White J, Clayborn A, McCarthy P, Abouharb S, Lim B, Litton JK, Ramirez DL, Saleem S, Stec J, Symmans WF, Huo L, Damodaran S, Sun R, Moulder SL. A phase II study of Mirvetuximab Soravtansine in triple-negative breast cancer. Invest New Drugs 39(2):509-515, 2021. e-Pub 2021. PMID: 32984932.
43. Roy M, Teshome M, Damodaran S, Sahin AA, Khazai L, Arribas E, Candelaria RP, Scoggins ME, Lane DL, Giordano SH, Albarracin CT, Prieto VG, Nagarajan P. Male Mammary Paget Disease: A Tale of 2 Contrasting Cases. Am J Dermatopathol 42(12):981-985, 2020. e-Pub 2020. PMID: 33289978.
44. Damodaran S, Sember QC, Arun BK. Clinical implications of breast cancer tumor genomic testing. Breast J 26(8):1565-1571, 2020. e-Pub 2020. PMID: 32696498.
45. Pairawan S, Hess KR, Janku F, Sanchez NS, Mills Shaw KR, Eng C, Damodaran S, Javle M, Kaseb AO, Hong DS, Subbiah V, Fu S, Fogelman DR, Raymond VM, Lanman RB, Meric-Bernstam F. Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. Clin Cancer Res 26(8):1924-1931, 2020. e-Pub 2020. PMID: 31852833.
46. Litton JK, Scoggins ME, Hess KR, Adrada BE, Murthy RK, Damodaran S, DeSnyder SM, Brewster AM, Barcenas CH, Valero V, Whitman GJ, Schwartz-Gomez J, Mittendorf EA, Thompson AM, Helgason T, Ibrahim N, Piwnica-Worms H, Moulder SL, Arun BK. Neoadjuvant talazoparib for patients with operable breast cancer with a germline BRCA pathogenic variant. Journal of Clinical Oncology 38(5):JCO1901304, 2020. e-Pub 2020. PMID: 31461380.
47. Ueno NT, Tahara RK, Fujii T, Reuben JM, Gao H, Saigal B, Lucci A, Iwase T, Ibrahim NK, Damodaran S, Shen Y, Liu DD, Hortobagyi GN, Tripathy D, Lim B, Chasen BA. Phase II study of Radium-223 dichloride combined with hormonal therapy for hormone receptor-positive, bone-dominant metastatic breast cancer. Cancer Med 9(3):1025-1032, 2020. e-Pub 2020. PMID: 31849202.
48. Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Meric-Bernstam F, Sahin AA. HER2 somatic mutation analysis in breast cancer: correlation with clinicopathological features. Hum Pathol 24(92):32-8, 2019. e-Pub 2019. PMID: 31351155.
49. Meric-Bernstam F, Zheng X, Shariati M, Damodaran S, Wathoo C, Brusco L, Demirhan ME, Tapia C, Eterovic AK, Basho RK, Ueno NT, Janku F, Sahin A, Rodon J, Broaddus R, Kim TB, Mendelsohn J, Mills Shaw KR, Tripathy D, Mills GB, Chen K. Survival outcomes by TP53 mutation status in metastatic breast cancer. JCO Precision Oncology 2018, 2018. e-Pub 2018. PMID: 30035249.
50. Datta J, Damodaran S, Parks H, Ocrainiciuc C, Miya J, Yu L, Gardner EP, Samorodnitsky E, Wing MR, Bhatt D, Hays J, Reeser JW, Roychowdhury S. Akt Activation Mediates Acquired Resistance to Fibroblast Growth Factor Receptor Inhibitor BGJ398. Mol Cancer Ther 16(4):614-624, 2017. e-Pub 2017. PMID: 28255027.
51. Damodaran S, Miya J, Kautto E, Zhu E, Samorodnitsky E, Datta J, Reeser JW, Roychowdhury S. Cancer Driver Log (CanDL): Catalog of Potentially Actionable Cancer Mutations. J Mol Diagn 17(5):554-9, 2015. e-Pub 2015. PMID: 26320871.
52. Samorodnitsky E, Jewell BM, Hagopian R, Miya J, Wing MR, Lyon E, Damodaran S, Bhatt D, Reeser JW, Datta J, Roychowdhury S. Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing. Hum Mutat 36(9):903-14, 2015. e-Pub 2015. PMID: 26110913.
53. Samorodnitsky E, Datta J, Jewell BM, Hagopian R, Miya J, Wing MR, Damodaran S, Lippus JM, Reeser JW, Bhatt D, Timmers CD, Roychowdhury S. Comparison of custom capture for targeted next-generation DNA sequencing. J Mol Diagn 17(1):64-75, 2015. e-Pub 2015. PMID: 25528188.
54. Damodaran S, Mrozek E, Liebner D, Kendra K. Focal takotsubo cardiomyopathy with high-dose interleukin-2 therapy for malignant melanoma. J Natl Compr Canc Netw 12(12):1666-70; quiz 1670, 2014. e-Pub 2014. PMID: 25505207.
55. Zhao W, Damodaran S, Villalona-Calero MA. From single-gene to multiplex analysis in lung cancer, challenges and accomplishments: a review of a single institution's experience. Lung Cancer Manag 4(3):315-324, 2014. e-Pub 2014. PMID: 25580159.
56. Damodaran S, Bellavia T, Sait SN, Wang ES, Wetzler M, Khushalani NI. Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer. Clin Colorectal Cancer 11(2):151-4, 2012. e-Pub 2012. PMID: 22133502.
57. Miecznikowski JC, Damodaran S, Sellers KF, Rabin RA. A comparison of imputation procedures and statistical tests for the analysis of two-dimensional electrophoresis data. Proteome Sci 8:66, 2010. e-Pub 2010. PMID: 21159180.
58. Damodaran S, Wood TD, Nagarajan P, Rabin RA. Evaluating peptide mass fingerprinting-based protein identification. Genomics Proteomics Bioinformatics 5(3-4):152-7, 2007. e-Pub 2007. PMID: 18267296.
59. Damodaran S, Rabin RA. Minimizing variability in two-dimensional electrophoresis gel image analysis. OMICS 11(2):225-30, 2007. e-Pub 2007. PMID: 17594240.
60. Damodaran S, Dlugos CA, Wood TD, Rabin RA. Effects of chronic ethanol administration on brain protein levels: a proteomic investigation using 2-D DIGE system. Eur J Pharmacol 547(1-3):75-82, 2006. e-Pub 2006. PMID: 16978605.
61. Vadivelu MK, Damodaran S Solomon J, Rajaseharan A. Distribution of ABO blood groups in acute leukaemias and lymphomas. Ann Hematol 83(9):584-7, 2004. e-Pub 2004. PMID: 15175895.

Invited Articles

1. Damodaran S, Roychowdhury S. Genomics and Precision Cancer Medicine. Oncology & Hematology Review 11(2):145-6, 2015. e-Pub 2015.

Review Articles

1. Bili Newman A, Damodaran S, Meric-Bernstam F. Antibody-drug conjugates in breast cancer: Progress and future directions. Cell Rep Med 7(5):102742, 2026. e-Pub 2026. PMID: 41950928.
2. Singareeka Raghavendra, A, Damodaran, S, Barcenas, CH, Fuqua, SW, Layman, RM, Tripathy, D. Personalizing therapies over the course of hormone receptor-positive/HER2-negative metastatic breast cancer. Ca-A Cancer Journal for Clinicians 76(1), 2026. e-Pub 2026. PMID: 41524544.
3. Sahin, AA, Chen, H, Xiao, H, Damodaran, S, Meric-Bernstam, F. Emerging molecular Therapeutic targets in breast Cancer. Human Pathology 162, 2025. e-Pub 2025. PMID: 40759284.
4. Sridhar, N, Iwase, T, Xie, X, Lee, J, Damodaran, S, Ueno, NT. Paving the path ForwARd. Cancer Treatment Reviews 138, 2025. e-Pub 2025. PMID: 40424861.
5. Damodaran S, Majumder S, Ramaswamy R. Endocrine resistance: mechanisms and therapeutic targets. Clinical Investigation 3(7):681-690, 2013. e-Pub 2013.
6. Damodaran S, Olson EM. Targeting the human epidermal growth factor receptor 2 pathway in breast cancer. Hosp Pract (1995) 40(4):7-15, 2012. e-Pub 2012. PMID: 23299030.
7. Damodaran S. Cocaine and beta-blockers: the paradigm. Eur J Intern Med 21(2):84-6, 2010. e-Pub 2010. PMID: 20206876.

Editorials

1. Damodaran S, Hortobagyi GN. Estrogen Receptor: A Paradigm for Targeted Therapy. Cancer Res 81(2021; 81:5396-8):5396-5398, 2021. PMID: 34725132.

Abstracts

1. Raghavendra AS, Tarasov A, Mouabbi JA, Evdokimova A, Smirnov V, Rumyantsev K, Barcenas CH, Layman RM, Savin E, Lim B, Pohlmann PR, Damodaran S, Hensley M, Makani N, Ogloblina A, Fowler NH, Giordano SH, Bagaev A, Yam C, Tripathy D. Real-world clinical utility of comprehensive genomic and transcriptomic profiling in metastatic breast cancer (mBC). American Society of Clinical Oncology, 2026. e-Pub 2026.
2. Chen H, Wang Z, Ding Q, Perkins B, Liu A, Sweeney K, Roy-Chowdhuri S, Huang X, Damodaran S, Huo L. Utility of PTEN Copy Number Variation by Next Generation Sequencing in Detecting PTEN Loss in Triple Negative Breast Cancer. United States and Canadian Academy of Pathology, 2026. e-Pub 2026.
3. Perkins B, Liu A, Ding Q, Wang Z, Sweeney K, Roy-Chowdhuri S, Huang X, Huo L, Clinton Y, Damodaran S, Chen H. PTEN Protein Expression and PI3K Pathway Genomic Alterations in Triple Negative Breast Cancer. United States and Canadian Academy of Pathology, 2026. e-Pub 2026.
4. McGhie A, Grannan EM, Zheng A, Cherian S, Newman AB, Layman RM, Damodaran S. Incidence of Hypersensitivity Reactions in Patients Receiving Trastuzumab Biosimilars. San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
5. Yam C, Radko A, Huo L, Singareeka A, Ohanjanyan E, Yudina A, Kushnarev V, Hill H, Abouharb S, Adrada B, Arun B, Barcenas C, Bisen A, Brewster A, Buzdar A, Mac Gregor MC, Damodaran S, Garber H, Guirguis M, Hassan A, Ibrahim N, Karuturi M, Kong E, Layman R, Moscol G, Mouabbi J, Murthy R, Nasrazadani A, Nelson B, Iheme AN, Oke O, Patel M, Pohlmann P, Ramirez D, Saleem S, Sukumar J, Sun J, Thomas P, Walters R, Wei P, Williams M, Wright M, Woodward WA, Hunt KK, Litton JK, Valero V, Tripathy D, Rauch G, Goldberg M, Korkut A. Circulating Immune Correlates of Pathological Response to Neoadjuvant Pembrolizumab Plus Chemotherapy in High-Risk, Early-Stage Triple-Negative Breast Cancer. San Antonio Breast Conference Symposium, 2025. e-Pub 2025.
6. Newman AB, Bonini F, Albarracin C, Damodaran S, Ferrarotto R. Reassessing Systemic Therapy in Breast Adenoid Cystic Carcinoma: Insights from a Large Retrospective Cohort. San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
7. Mughees M, Pathania R, Fowlkes N, Wang J, Krishnamurthy S, Damodaran S, Woodward WA, Hunt KK, Sahin AA, Dalby K, Bartholomeusz AC. Combination of a novel MELK inhibitor with standard of care treatment results in tumor regression and improved survival in a triple-negative inflammatory breast cancer xenograft model. San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
8. Goetz MP, Wander SA, Bachelot T, Curigliano G, Nonneville AD, Gal-Yam EN, Sammons SL, Shen S, Twelves C, Gasper G, Plourde PV, Portman DJ, Damodaran S. Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation. San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
9. Newman AB, Raghavendra A, Grannan E, Meric-Bernstam F, Tripathy D, Litton J, Damodaran S. Sacituzumab Govitecan Dosing and Neutropenia Risk in Patients with HER2-Negative Metastatic Breast Cancer. San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
10. Raghavendra AS, Wang Z, Bassett R, Damodaran S, Yam C, Valero V, Pohlmann P, Litton JK, Meric-Bernstam F, Tripathy D, Adesoye T. Real world outcomes of sacituzumab govitecan in hormone receptor-positive and triple-negative breast cancer: Impact of prior therapy. San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
11. Raghavendra AS, Qiao W, Gutierrez AM, Layman R, Damodaran S, Arun BK. Prognostic Impact of BRCA Mutation Status on Outcomes with CDK4/6 Inhibitor Therapy in HR+/HER2- Metastatic Breast Cancer: A Real-World Cohort Study. San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
12. Damodaran S, Iwase T, Marx A, Yuan Y, Kai M, Willey JS, Meric-Bernstam F, Tripathy D, Barcenas CH, Lee J, Ueno NT. Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer. San Antonio Breast Cancer Symposium, 2025. e-Pub 2025.
13. Reddy TP, Kang L, Le H, Damodaran S, Raghav K, Kopetz S, Ahnert JR, Dumbrava EE, Yap TA, Williams S, Routbort MJ, Patel KP, Meric-Bernstam F. Emergence of TOP1 mutations as a potential biomarker of resistance to topoisomerase-targeting regimens. AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics, 2025. e-Pub 2025.
14. Valero V, Wang Z, Damodaran S, Bassett R, Meric-Bernstam F, Tripathy D, Litton JK, Raghavendra AS. Outcomes of subsequent antibody drug conjugate (ADC) regimen in ADC-resistant HER2 low metastatic breast cancer. European Society of Medical Oncology, 2025. e-Pub 2025.
15. Naito Y, Tolaney SM, Damodaran S, Meric-Bernstam F, Modi S, Mohapatra A, Iko Y, He S, Nakajima K, Ueno NT. Valemetostat and Trastuzumab Deruxtecan (T-DXd) in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Low, Previously Treated, Unresectable or Metastatic Breast Cancer. Japanese Breast Cancer Society, 2025. e-Pub 2025.
16. Raghavendra AS, Qaio W, Shen Y, Damodaran S, Tripathy D. Real-world study of treatment patterns and outcomes in HR+/HER2- metastatic breast cancer patients after progression on CDK4/6 inhibitor therapy. ESMO Breast Cancer, 2025. e-Pub 2025.
17. Raso MG, Toro EB, Li J, Pandurengan R, Batra H, Tang X, Rico DO, Perez JM, Gomez JS, Damodaran S, Thompson A, Machl A, Jacob N, Litton JK, Murthy RK, Haymaker C. Multiplex immunofluorescence based spatial analysis of HER2 positive breast cancer patients treated with bintrafusp alfa: A translational pathology study. American Association For Cancer Research, 2025. e-Pub 2025.
18. Naito Y, Tolaney SM, Damodaran S, Meric-Bernstam F, Modi S, Mohapatra A, Iko Y, He S, Nakajima K, Ueno NT. Valemetostat Plus Trastuzumab Deruxtecan (T-DXd) or Datopotamab Deruxtecan (Dato-DXd) in Patients With Solid Tumor. Japanese Society of Medical Oncology, 2025. e-Pub 2025.
19. Gouda M, Gonugunta A, Ecaterina, Dumbrava, Yap TA, Rodon J, Piha-Paul SA, Pohlmann PR, Damodaran S, Murthy R, Valero V, Mouabbi J, Tripathy D, Aysegul, Sahin, Chen H, Meric-Bernstam F. HER2 Loss Following Treatment with Trastuzumab Deruxtecan in Patients with Metastatic Breast Cancer. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
20. Goetz M, Wander SA, Bachelot T, Curigliano G, Nonneville AD, Gal-Yam EN, Sammons SL, Shen S, Twelves C, Plourde PV, Portman DJ, Damodaran S. Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
21. Vidula N, Damodaran S, Bhave M, Blouch E, Ogbenna O, Abramson V, Shah A, Flaum L, Cristofanilli M, Sparano J, Ostrer H, Horick N, Rugo HS, Bardia A. Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
22. Raghavendra AS, Wang Z, Jr RB, Tripathy D, Arun B, Damodaran S. Impact of gBRCA1/2 Status on Survival Outcomes in Metastatic Breast Cancer Patients Treated with Topoisomerase 1 based AntibodyDrug Conjugates (ADCs). San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
23. Raghavendra AS, Wang Z, Jr RB, Tripathy D, Damodaran S. Survival Outcomes of Sequential Topoisomerase I AntibodyDrug Conjugate Therapies in Metastatic Breast Cancer Patients. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
24. Raghavendra AS, Wang Z, Jr RB, Damodaran S, Tripathy D. Impact of Inflammatory Breast Cancer on Survival Outcomes in Metastatic Breast Cancer Patients Treated with Topoisomerase 1 based Antibody-Drug Conjugates (ADCs. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
25. Raghavendra AS, Kettner NM, Kwiatkowski D, Damodaran S, Yan, Wang, Ramirez D, Gombos DS, Hunt KK, Shen Y, Keyomarsi K, Tripathy D. Phase I Safety and Efficacy Study of Autophagy Inhibition to Augment the Antiproliferative and Biological Effects of Low Dose Palbociclib plus Letrozole in Estrogen Receptor-Positive, HER2-negative Metastatic Breast Cancer (MBC). San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
26. Iwase T, Damodaran S, Marx A, Meric-Bernstam F, Tripathy D, Barcenas CH, Lee J, Ueno NT. Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
27. Tolaney SM, Damodaran S, MericBernstam F, Modi S, Naito Y, Mohapatra A, Iko Y, He S, Nakajima K, Ueno NT. Valemetostat and Trastuzumab Deruxtecan in Patients With HER2-Low, Previously Treated, Unresectable or Metastatic Breast Cancer. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
28. Mughees M, Tan A, Wang J, Savitri, Krishnamurthy, Damodaran S, Tripathy D, Woodward WA, Dalby K, Bartholomeusz C. MELK controls stromal components through fibronectin modulation in highly aggressive breast cancers. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
29. Thai Z, Philipovskiy A, Wang J, Yardley D, Cook D, Damodaran S. An Open Label Study of BTX-A51 in Patients with ER+/HER2- GATA3 Mutant and Wild Type Metastatic Breast Cancer. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
30. Mouabbi J, Nasrazadani A, Senthil, Damodaran, Kushnarev V, Goncharova D, Baranov O, Chernyshov K, Kust S, Kotlov N, Clayton P, Pohlmann P, Tripathy D, MericBernstam F. Comprehensive Analysis of ADC Target Expression in Invasive Lobular Carcinoma. San Antonio Breast Cancer Symposium, 2024. e-Pub 2024.
31. Li J, Otte H, Raso G, Toro EB, Gomez JS, Damodaran S, Litton JK, Murthy R, Haymaker C. Exploration of circulating immunoprofiling at baseline in different subtypes of breast cancer patients . Society for Immunotherapy of Cancer, 2024. e-Pub 2024.
32. Goetz MP, Wander SA, Bachelot T, Batist G, Cortes J, Cristofanilli M, Curigliano G, De Nonneville A, Gal-Yam EN, Jhaveri KL, Ma CX, Parsons HA, Rugo HS, Sammons SL, Stover DG, Twelves C, Bardia A, Plourde PV, Portman DJ, Damodaran S. Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating ER+/HER2-, locally advanced or metastatic breast cancer with an ESR1 mutation. American Society of Clinical Oncology, 2024. e-Pub 2024.
33. Iwase T, Damodaran S, Marx A, Meric-Bernstam F, Tripathy D, Barcenas CH, Lee J, Ueno NT. Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer. American Society of Clinical Oncology, 2024. e-Pub 2024.
34. Cheng Y, Zhang X, Liu J, Huang Z, Lv D, Zhang Y, Chaudhry A, Amin H, Damodaran S, Patel SB, Assad H, Lee AS, Zhao H, Bai J, Xue T, Chin S. YL202/BNT326, a HER3-targeted ADC in patients with locally advanced or metastatic non-small cell lung cancer and breast cancer: Preliminary results from a first-in-human phase 1 trial. American Society of Clinical Oncology, 2024. e-Pub 2024.
35. Vidula N, Damodaran S, Bhave MA, Blouch EL, Ogbenna O, Flaum LE, Shah AN, Abramson V, Cristofanilli M, Sparano J, Ostrer H, Horick N, Rugo H, Bardia A. Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping. American Society of Clinical Oncology Annual Meeting, 2024. e-Pub 2024.
36. Luo L, Yang P, Mastoraki S, Wang Y, Kettner NM, Raghavendra AS, Tripathy D, Damodaran S, Hunt KK, Li Z, Keyomarsi K. Single-Cell RNA Sequencing Reveals Metastatic Site-Specific Biomarkers for Predicting Response to CDK4/6 Inhibition in Advanced HR+/HER2- Breast Cancer. American Association For Cancer Research, 2024. e-Pub 2024.
37. Goetz MP, Wander SA, Bachelot T, Batist G, Cortes J, Cristofanilli MA, Curigliano G, Nonneville A, Gal-Yam EN, Jhaveri K, Ma C, Parsons HA, Rugo HS, Sammons SL, Stover DG, Twelves C, Bardai A, Plourde PV, Portman DJ, Damodaran S. Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation. San Antonio Breast Cancer Symposium, 2023. e-Pub 2023.
38. Damodaran S, Plourde PV, Jenkins SN, Mayer P, Portman DJ, Goetz MP. Pharmacokinetics (PK) of lasofoxifene (LAS) monotherapy and combined with abemaciclib (Abema). San Antonio Breast Cancer Symposium, 2023. e-Pub 2023.
39. Damodaran S, Iwase T, Marx A, Yuan Y, Kai M, Willey JS, Meric-Bernstam F, Tripathy D, Barcenas CH, Lee J, Ueno NT. Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in subjects with HER2 low/ultra-low/null metastatic breast cancer. San Antonio Breast Cancer Symposium, 2023. e-Pub 2023.
40. Damodaran S, Andre F, Unni N, Ferreira M, Giridhar K, Daniel BR, Colleoni M, Costa L, Bachelot T, O’Brien C, Wright GLS, Shimura M, Tomlinson G, Gil M, Turner NC. Final Results from the Phase 2, Open-Label FOENIX‑MBC2 Study: Efficacy and Safety of Futibatinib in Adult Patients with Locally Advanced/Metastatic HR+/HER2− Breast Cancer Harboring High-Level FGFR1 Gene Amplification. San Antonio Breast Cancer Symposium, 2023. e-Pub 2023.
41. Vidula N, Damodaran S, Blouch EL, Horick N, Ruffle-Deignan NR, Bhave M, Shah AN, Varella L, Abramson V, Sparano J, Ellisen L, Alim I, Ostrer O, Rugo H, Bardia A. Phase II study of talazoparib, a PARP inhibitor, in somatic BRCA1/2 mutant metastatic breast cancer identified by cell-free DNA or tumor tissue genotyping. San Antonio Breast Cancer Symposium, 2023. e-Pub 2023.
42. Damodaran S, F Moore HC, Anderson IC, Cherian M, O’Sullivan CC, Plourde PV, Portman DJ, Goetz MP. Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update. Metastatic Breast Cancer Research Conference, 2023. e-Pub 2023.
43. Mouabbi J, Meric-Bernstam F, Turova P, Chernyshov K, Kushnarev V, Kotlov N, Brown JH, Clayton P, Nomie K, Fowler N, Tripathy D, Damodaran S. Genomic characterization of the GATA3 mutational landscape in breast cancer. American Society of Clinical Oncology, 2023. e-Pub 2023.
44. Vidula N, Damodaran S, Bhave MA, Rugo HS, Blouch EL, Ruffle-Deignan NR, Shah AN, Cristofanilli M, Abramson VG, Sparano JA, Ostrer H, Horick NK. Phase II study of a PARP inhibitor in somatic BRCA1/2 mutant metastatic breast cancer (MBC). American Society of Clinical Oncology, 2023. e-Pub 2023.
45. Damodaran S, Moore HCF, Anderson IC, Cherian MA, O’Sulllivan CC, Plourde PV, Portman DJ, Goetz MP. Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update. American Society of Clinical Oncology, 2023. e-Pub 2023.
46. Meric-Bernstam F, Yuca E, Evans K, Gabriela Raso MZ, Maejima T, Xiaofeng, Zheng, Rizvi YQ, Akcakanat A, Scott S, Wang B, Byers L, Tripathy D, Okajima D, Damodaran S. Antitumor activity of TROP2 antibody drug conjugate datopotamab deruxtecan in chemotherapy-resistant breast cancer models. European Society of Medical Oncology, 2023. e-Pub 2023.
47. Nelson BE, Janku F, Fu S, Dumbrava EI, Hong DS, Karp D, Naing A, Rodon J, Tsimberidou A, Amaria RN, Conley A, Damodaran S, Raghav KP, Kreider BL, Tung, D, Varterasian M, Khazaie K, Piha-Paul S. Phase Ib Study of Pembrolizumab in Combination with Intratumoral Injection of Clostridium novyi-NT in Patients with Advanced Solid Tumors. American Association For Cancer Research, 2023. e-Pub 2023.
48. Bardia A, Krop IE, Juric D, Kogawa T, Hamilton EP, Spira AI, Mukohara T, Tsunoda T, Damodaran S, Meric-Bernstam F. Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer. Miami Breast Cancer Conference, 2023. e-Pub 2023.
49. Kogawa T, Meric-Bernstam F, Krop I, Juric D, Hamilton EP, Spira AI, Mukohara T, Tsunoda T, Damodaran S, Greenberg J, Gu W, Kobayashi F, Zebger-Gong H, Kawasaki Y, Wong R, Bardia A. Datopotamab Deruxtecan in Advanced Hormone Receptor +, HER2- Breast Cancer; a Phase 1 TROPION-PanTumor01 Study. Japanese Society of Medical Oncology, 2023. e-Pub 2023.
50. Meric-Bernstam F, Krop I, Juric D, Hamilton E, Spira AI, Mukohara T, Tsunoda T, Damodaran S, Greenberg J, Gu W, Kobayashi F, Zebger-Gong H, Kawasaki Y, Wong R, Bardia A. Phase 1 TROPION-PanTumor01 Study Evaluating Datopotamab Deruxtecan (Dato-DXd) in Unresectable or Metastatic Hormone Receptor–Positive/HER2–Negative Breast Cancer (BC). San Antonio Breast Cancer Symposium, 2022. e-Pub 2022.
51. Damodaran S, Moore H, O’Sulllivan CC, Plourde PV, Riordan G, Sloane HS, Tripathy D, Carroll D, Portman D. Estrogen receptor 1 (ESR1) mutations in circulating tumor DNA (ctDNA) from patients with ER+/HER2- metastatic breast cancer (mBC) treated with lasofoxifene plus abemaciclib in the ELAINE 2 study. San Antonio Breast Cancer Symposium, 2022. e-Pub 2022.
52. Yam C, Li Z, Korkut A, Ma W, Kong E, Hill HA, Abbas H, Abouharb S, Adrada B, Arun BK, Barcenas CH, Bisen A, Booser D, Buzdar A, Candelaria R, Chen J, Clayborn A, Damodaran S, Ding Q, Garber H, Hortobagyi GN, Hunt KK, Ibrahim NH, Iheme A, Karuturi MS, Koenig K, Layman RM, Lee J, Litton JK, Mitchell M, Moscol G, Mouabbi J, Murthy RK, Oke O, Pohlmann P, Ramirez D, Ravenberg E, Saleem S, Teshome M, Valero V, White J, Williams M, Woodward W, Yajima C, Ueno NT, Chen K, Rauch G, Huo L, Tripathy D. Clinical and Molecular Characteristics of HER2-low/zero Early Stage Triple- Negative Breast Cancer. San Antonio Breast Cancer Symposium, 2022. e-Pub 2022.
53. Damodaran S, Liu D, Schwartz J, Valero V, Ramirez R, Saleem S, Ueno NT, Ibrahim NK, Karuturi MS, Murthy RK, Moulder S, Litton JK. A phase Ib trial of bintrafusp alfa and eribulin in patients with metastatic triple negative breast cancer (TNBC. San Antonio Breast Cancer Symposium, 2022. e-Pub 2022.
54. Damodaran S, Plourde PV, Moore CF H, Anderson IC, Portman DJ. Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies. American Society of Clinical Oncology, 2022. e-Pub 2022.
55. Blau S, Peguero J A, Moore CF H, Anderson IC, Barve MA, Cherian MA, Elkhanany A, O”Sullivan, CCM, Moreno-Aspitia A, Gleich LL, Riesen K, Ezzati R, Degele M, Shulman M, Stempf S, Cooney MM, Damodaran S. Operational metrics for the ELAINE II study combining a traditional approach with a just-in-time model. American Society of Clinical Oncology, 2022. e-Pub 2022.
56. Nelson BE, Saleem S, Damodaran S, Somiah N, Piha-Paul SA, Moore JA, Yilmaz B, Karp DD, Dumbrava EE, Tsimberidou AM, Hong DS, Ahnert JR, Booser D, Ibrahim NK, Conley AP, Bhosale P, Hernandez CMR, Tripathy D, Naing A, Meric-Bernstam F. Phase Ib study of selinexor and eribulin combination in advanced solid tumors and triple-negative breast cancer. American Society of Clinical Oncology, 2022. e-Pub 2022.
57. Krop I, Juric D, Shimizu T, Tolcher A, Spira A, Mukohara T, Lisberg AE, Kogawa T, Papadopoulos KP, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A. Datopotamab Deruxtecan in Advanced/Metastatic TNBC: Results From a Phase 1 TROPION-PanTumor01 Study. Japanese Breast Cancer Society, 2022. e-Pub 2022.
58. Meric-Bernstam F, Krop IE, Juric D, Kogawa T, Hamilton EP, Spira AI, Mukohara T, Tsunoda T, Damodaran S, Greenberg J, Gu W, Kobayashi F, Zebger-Gong H, Kawasaki Y, Wong R, Bardia A. TROPION-PanTumor01 Trial: First Results of Datopotamab Deruxtecan (Dato-DXd), a TROP2-Directed Antibody Drug Conjugate (ADC), in Patients (Pts) with Hormone Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Breast Cancer (BC). ESMO Breast Cancer, 2022. e-Pub 2022.
59. Navarro-Yepes J, Kettner NK, Bui T, Raghavendra AS, Rao X, Wang J, Sahin A, Damodaran S, Tripathy D, Hunt KK, Keyomarsi K. Differential mechanisms of acquired resistance to palbociclib reveals pathways of response to abemaciclib. American Association For Cancer Research, 2022. e-Pub 2022.
60. Minussi DC, Wang J, Schalck A, Yan Y, H-J W, Peng C, Hu M, Sei E, Edgerton M, Chen H, Contreras A, Hui D, Damodaran S, Kopetz S, Lim B, Navin N. Resolving clonal substructure from single cell genomic data in primary and metastatic tumors using CopyKit. American Association For Cancer Research, 2022. e-Pub 2022.
61. Yuca E, Evans K, Akcakanat A, Raso G, Rizvi YQ, Yang F, Byers L, Damodaran S, Daisuke O, Meric-Bernstam F. Anti-tumor activity and biomarker analysis for datopotamab deruxtecan in breast cancer PDX models. American Association For Cancer Research, 2022. e-Pub 2022.
62. Zhao M, DiPeri TP, Raso G, Zheng X, Rizvi YQ, Evans K, Yang F, Akcakanat A, Tripathy D, Dumbrava EI, Damodaran S, Meric-Bernstam F. Epigenetically upregulating TROP2 enhances therapeutic efficacy of TROP2 antibody drug conjugate sacitizumab govitecan. American Association For Cancer Research, 2022. e-Pub 2022.
63. Saridogan T, Akcakanat A, Zhao M, Evans KW, Yuca E, Scott S, Kirby BP, Zheng X, Damodaran S. Efficacy of futibatinib, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in breast cancer models with FGFR alterations. San Antonio Breast Cancer Symposium, 2021. e-Pub 2021.
64. Vidula N, Blouch E, Basile E, Horick N, Ruffle-Deignan N R, Damodaran S, Moreno-Aspitia A, Bhave M, Shah A, Liu MC, Sparano J, Ostrer H, Rugo HS, Ellisen L, Bardia A. Phase II study of a PARP inhibitor in metastatic breast cancer with somatic BRCA1/2 mutations identified by cell-free DNA: Genotyping based clinical trial. San Antonio Breast Cancer Symposium, 2021. e-Pub 2021.
65. Elshafeey N, Hwang KP, Adrada EB, Candelaria RP, Boge M, Mahmoud RM, Hm C, Sun J, Yang W, Kotrotsu A, Musall BC, Son JB, Whitman GJ, Leung J, Le-Petross H, Santiago L, Lane DL, Scoggins ME, Spak DA, Guirguis MS, Patel MM, Perez F, Abdelhafez AH, White JB, Huo L, E# R, Peng W, Thompson A, Damodaran S, Tripathy D, Moulder S, Yam C, Pagel MD, Ma J, Rauch GM. Radiomics model based on magnetic resonance image compilation (MagIC) as early predictor of pathologic complete response to neoadjuvant systemic therapy in triple-negative breast cancer. San Antonio Breast Cancer Symposium, 2021. e-Pub 2021.
66. Raghavendra AS, Ha MJ, Kettner NM, Damodaran S, Layman R, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone - A large institutional study. San Antonio Breast Cancer Symposium, 2021. e-Pub 2021.
67. Damodaran S, Unni N, Giridhar KV, Daniel B, Howell S, Costa L, Ferreira M, Shimura M, Tomlinson G, Gil M, Turner N. Futibatinib in combination with fulvestrant in patients with metastatic breast cancer (MBC) harboring high-level FGFR1 amplification: Preliminary data from a phase 2 study. San Antonio Breast Cancer Symposium, 2021. e-Pub 2021.
68. Krop I, Juric D, Shimizu T, Tochler A, Spira A, Mukohara T, Lisberg A E, Kogawa T, Papadopoulos K P, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F, Bardia A. Datopotamab deruxtecan in advanced/metastatic HER2- breast cancer: Results from the phase 1 TROPION-PanTumor01 study. San Antonio Breast Cancer Symposium, 2021. e-Pub 2021.
69. Bardia A, Juric D, Shimizu T, Tolcher A, Korim R, Spira A, Mukohara T, Lisberg AE, Togawa T, Krop I, Papadopoulos KP, Hamilton E, Damodaran S, Greenberg J, Gu W, Kobayashi F, Guevara F, Jikoh T, Kawasaki Y, Meric-Bernstam F. Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial. European Society of Medical Oncology, 2021. e-Pub 2021.
70. Yam C, Mittendorf EA, Sun R, Huo L, Damodaran S, Rauch GM, Candelaria RP, Adrada BE, Seth S, Symmans WF, Murthy RK, White J, Ravenberg E, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Tripathy D, Moulder SL, Litton JK. Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple- negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC). American Society of Clinical Oncology, 2021. e-Pub 2021.
71. Raghavendra AS, Kwiatkowski D, Damodaran S, Kettner NM, Ramirez DL, Gombos DS, Hunt K, Shen Y, Keyomarsi K, Tripathy D. Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC). American Society of Clinical Oncology, 2021. e-Pub 2021.
72. Vidula N, Blouch E, Horick NK, Basile E, Damodaran S, Liu MC, Shah AN, Moreno-Aspitia A, Rugo HS, Ellisen L, Bardia A. Phase II multicenter study of talazoparib for somatic BRCA1/2 mutant metastatic breast cancer. American Society of Clinical Oncology, 2021. e-Pub 2021.
73. Abuhadra A, Chag C, Yam C, White J, Ravenberg E, Lim B, Ueno NT, Litton JK, Arun B, Damodaran S, Murthy RK, Ibrahim NK, Hortobagyi GN, Valero V, Tripathy D, Thompson A, Mittendorf EA, Huo L, Moulder SL, Jeng RR. The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC). American Society of Clinical Oncology, 2021. e-Pub 2021.
74. Damodaran S, Plourde P V, Tripathy D, Jenkins S N, Portman D J. An Open-label, Multicenter Study Evaluating the Safety of Lasofoxifene in Combination with Abemaciclib for the Treatment of Pre- and Postmenopausal Women with Locally Advanced or Metastatic ER+/HER2− Breast Cancer and have an ESR1 Mutation. San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
75. Abuhadra N, Yam C, Sun R, Huo L, White J, Ravenberg E, Adrada B, Sahin A, Litton J, Lim B, Ueno N T, Arun B, Tripathy D, Damodaran S, Murthy R, Valero V, Hortobagyi G, Ibrahim N, Thompson A, Lucci A, Mittendorf E, Moulder S, Chang J. Prospective evaluation of patients with metaplastic (Mp) triple negative breast cancer (TNBC): Molecular characteristics and outcomes with neoadjuvant therapy (NAT). San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
76. Abuhadra N, Chang C, Yam C, Sun R, Huo L, White J, Ravenberg E, Litton J, Lim B, Ueno N T, Arun B, Tripathy D, Damodaran S, Murthy R, Valero V, Hortobagyi G, Ibrahim N, Thompson A, Mittendorf E, Moulder S, Jenq R. Prospective evaluation of the gut microbiome and response to neoadjuvant therapy (NAT) in early-stage triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
77. Damodaran S, Murthy R K, Nusrat M, Saigal B, Trager S C, Tripathy D, Meric-Bernstam F. Phase Ib/II trial of copanlisib in combination with trastuzumab and pertuzumab after induction treatment of HER2 positive metastatic breast cancer with PIK3CA mutation or PTEN mutation. San Antonio Breast Cancer Symposium, 2020. e-Pub 2020.
78. Basho R, Yam C, White J B, Zhao L, Huo L, Mittendorf E A, Thompson A M, Litton J K, Arun B, Lim B, Valero V, Tripathy D, Zhang J, Adrada B E, Santiago L, Ravenberg E, Moulder S L, Damodaran S. Incidence of PI3K pathway alteration and response to neoadjuvant therapy (NAT) in triple negative breast cancer (TNBC) subtypes. American Society of Clinical Oncology, 2020. e-Pub 2020.
79. Yam C, Alatrash G, E-Y Y, Garber H, Philips A V, Huo L, Yang F, Basset R L, Sun X, Cuentas E R, Symmans W F, Seth S, White J B, Rauch G M, Damodaran S, Litton J K, Wargo J A, Hortobagyi G N, Moulder S L, Mittendorf E A. Immune phenotype and response to neoadjuvant systemic therapy (NAST) in triple negative breast cancer (TNBC). American Society of Clinical Oncology, 2020. e-Pub 2020.
80. Damodaran S, Zhao F, Deming D A, Mitchell E P, Wright J J, Doyle L A, Gray R J, Shuli L, McShane L, Rubinstein L V, Patton D R, Williams M, Hamilton S R, Suga J M, Conley B A, Arteaga C L, Harris L, O’Dwyer P J, Chen A P, Flaherty K. Phase II study of copanlisib in patients with tumors with PIK3CA mutations (PTEN loss allowed): NCI MATCH EAY131-Z1F. American Society of Clinical Oncology 38(no. 15_suppl):) 3506-3506, 2020. e-Pub 2020.
81. Lim B, Seth S, Huo L, Layman R M, Valero V, Thompson A M, White J B, Litton J K, Damodaran S, Candelaria R P, Arun B, Rauch G M, Murthy R K, Ding Q, Symmans W F, Zhao L, Zhang J, Tripathy D, Moulder S L, Ueno N T. Comprehensive profiling of androgen receptor-positive (AR+) triple-negative breast cancer (TNBC) patients (pts) treated with standard neoadjuvant therapy (NAT) +/- enzalutamide. American Society of Clinical Oncology, 2020. e-Pub 2020.
82. Abuhadra N, Sun R, Litton J K, Rauch G M, Thompson A M, Lim B, Adrada B, Mittendorf E, Damodaran S, Pitpitan R, Arun B, White J, Ravenberg E, Santiago L, Sahin A, Murthy R, Ueno N T, Ibrahim N, Moulder S, Huo L. The immunomodulatory (IM) signature enhances prediction of pathologic complete response (pCR) to neoadjuvant therapy (NAT) in triple negative breast cancers (TNBC) with moderate stromal tumour infiltrating lymphocytes (sTIL). European Society of Medical Oncology, 2020. e-Pub 2020.
83. Dumbrava E, Damodaran S, Zheng X, Vukovic V, Pairawan S S, Hong D S, Piha-Paul S S, Ahnert J R, Pant S, Subbiah V, Yuan Y, Murthy R, Litton J K, Ferrari D M, Andreeff M, Tripathy D, Aivado M, Meric-Bernstam F. A phase Ib study of ALRN-6924 (MDM2/MDMX inhibitor) in combination with paclitaxel in wild- type (WT) TP53 metastatic solid tumors including estrogen receptor positive (ER+) breast cancer. American Society of Clinical Oncology, 2020. e-Pub 2020.
84. Ileana Dumbrava EE, Damodaran S, Zheng X, Vukovic V, Pairawan SS, Hong DS, Piha-Paul SA, Rodon J, Pant S, Subbiah V, Yuan Y, Murthy R, Tapia C, Litton J, Ferrari D, Andreeff M, Tripathy D, Aivado M, Meric-Bernstam F. A Phase 1b Study of ALRN-6924 in Combination with Paclitaxel in Wild-type (WT) TP53 Metastatic Solid Tumors including Estrogen-Receptor Positive Breast Cancer. American Association For Cancer Research, 2020. e-Pub 2020.
85. Roy M, Ma J, Sahin A A, Damodaran S, Tetzlaff M T, Curry J L, Ciura A M, Ning J, Torres-Cabala C, Ivan D, Aung P P, Ross M I, Gershenwald J E, Davies M A, Prieto V G, Nagarajan P. Primary cutaneous melanoma of the breast in women. A retrospective study of 82 patients. San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
86. Adrada B E, Abdelhafez A H, Musall B C, Hess K R, Son J B, Pagel M D, Hwang K, Candelaria R P, Santiago L, Whitman G J, Le-Petross H, Moseley T W, Arribas E, Lane D L, Scoggins M E, Spak D A, Leung J, Damodaran S, Lim B, Valero V, White J W, Thompson A M, Litton J K, Moulder S L, Ma J, Yang W T, Rauch G M. Quantitative apparent diffusion coefficient (ADC) radiomics of tumor and peritumoral regions as potential predictors of treatment response to neoadjuvant chemotherapy (NACT) in triple negative breast cancer (TNBC) patients. San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
87. Abuhadra N, Hess K R, Litton J K, Rauch G M, Thompson A M, Lim B, Adrada B, Mittendorf E A, Damodaran S, Candelaria R P, Arun B, Yang W T, Ueno N T, Santiago L, Murthy R K, Ibrahim N K, Sahin A S, Symmans W F, Huo L, Moulder S L. Serial TILs: Evaluating the role of mid-treatment tumor infiltrating lymphocytes (TIL) in predicting pathologic complete response (pCR) in early-stage triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
88. Damodaran S, Litton J K, Hess K R, Eppig C T, Grzegorzewski K, Meric-Bernstam F, Wistuba I, White J B, Rauch G M, Candelaria R P, Adrada B, Lim B, Moulder S L, Tripathy D. A Phase-2, Two-Cohort Trial of Neoadjuvant Nab-Paclitaxel and Alpelisib in Anthracycline Refractory Triple Negative Breast Cancer with PIK3CA or PTEN alterations. San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
89. Garber H, Rauch G M, Adrada B, Candelaria R P, Mittendorf E A, Thompson A M, Litton J K, Damodaran S, Lim B, Arun B, Ueno N T, Valero V, Ibrahim N K, Murthy R K, Tripathy D, Piwnica-Worms H, Symmans W F, Huo L, Moulder S L. Residual cancer burden in patients with early stage triple negative breast cancer who progress on anthracycline-based neoadjuvant chemotherapy in an ongoing clinical trial (ARTEMIS). San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
90. Rauch G M, Abdelhafez A H, Musall B C, Hess K R, Son J B, Pagel M D, Hwang K, Candelaria R P, Santiago L, Whitman G J, Le-Petross H, Moseley T W, Arribas E, Lane D L, Scoggins M E, Spak D A, Leung J, Damodaran S, Lim B, Valero V, White J W, Thompson A M, Litton J K, Moulder S L, Ma J, Yang W T, Adrada B E. Radiomics of quantitative apparent diffusion coefficient (ADC) from fibroglandular tissue (FGT) for prediction of tumor infiltrating lymphocytes (TIL) levels and neoadjuvant chemotherapy treatment (NACT) response in triple negative breast cancer (TNBC). San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
91. Turner N C, Krop I E, Bardia A, Damodaran S, Martin M, Benhadji K A, He Yaohua H, Ptaszynski M, Arteaga C L. A phase 2 study of futibatinib (TAS-120) in metastatic breast cancers harboring fibroblast growth factor receptor (FGFR) amplifications (FOENIX-MBC2). San Antonio Breast Cancer Symposium, 2019. e-Pub 2019.
92. Musall BC, Rauch GM, Adrada BE, Abdelhafez AH, Candelaria RP, Yang WT, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Leung JW, Pagel MD, Hwang K, Hess KR, Son JB, Willis BJ, Litton JK, Damodaran S, Lim B, Thompson AM, Moulder SL, Ma J. First-Order Radiomics of Quantitative Apparent Diffusion Coefficient (ADC) Are Potential Predictors of Treatment Response to Neoadjuvant Chemotherapy (NACT) in Triple Negative Breast Cancer (TNBC) Patients. Radiological Society of North America, 2019. e-Pub 2019.
93. Abdel Hameed AH, Adrada BE, Musall B, Ma J, Candelaria RP, Yang WT, MD, Hess K, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas EM, Lane DL, Scoggins ME, Leung JW, Pagel MD, Hwang K, Son JB, Litton J, Damodaran S, Lim B, White J, Mahmoud HS, Valero V, Thompson A, Moulder S, Rauch GM. Tumor Necrosis at Baseline Dynamic Contrast Enhanced (DCE) MRI for Prediction of Neoadjuvant Chemotherapy Treatment (NACT) Response in Triple Negative Breast Cancer (TNBC) Patients. Radiological Society of North America, 2019. e-Pub 2019.
94. Musall BC, Ma J, Adrada BE, Abdelhafez AH, Candelaria RP, Yang WT, Santiago L, Whitman GJ, Le-Petross H, Moseley TW, Arribas E, Lane DL, Leung JW, Pagel MD, Hwang K, Hess KR, Son JB, White JB, Litton JK, Damodaran S, Lim B, Mahmoud HS, Megahed A, Thompson AM, Moulder SL, Rauch GM. Quantitative Tumor Volumes by Fast Dynamic Contrast Enhanced (DCE) MRI Predict Treatment Response to Neoadjuvant Chemotherapy (NACT) In Triple Negative Breast Cancer (TNBC) Patients. Radiological Society of North America, 2019. e-Pub 2019.
95. Litton JK, Damodaran S, Wistuba II, Yang F, Contreras A, Tam A, Ojalvo L, Dussault I, Helberg C, Moulder S. Bintrafusp alfa (M7824) and eribulin mesylate in treating patients with metastatic triple negative breast cancer (TNBC)(NCT03579472). European Society of Medical Oncology, 2019. e-Pub 2019.
96. Abuhadra N, Hess KR, Litton JK, Rauch GM, Thompson AM, Lim B, Adrada BE, Mittendorf EA, Damodaran S, Candelaria RP, Arun B, Yang WT, Ueno NT, Santiago L, Murthy RK, Ibrahim NK, Sahin AA, Symmans WF, Moulder SL, Huo L. Beyond TILs: Predictors of pathologic complete response (pCR) in triple-negative breast cancer (TNBC) patients with moderate tumor-infiltrating lymphocytes (TIL) receiving neoadjuvant therapy. American Society of Clinical Oncology, 2019. e-Pub 2019.
97. Seth S, Crespo J, Huo L, Thompson AM, Mittendorf EA, Hess KR, Litton JK, Rauch GM, Adrada BE, Damodaran S, Candelaria RP, Arun B, Yang WT, Santiago L, Murthy RK, Sahin AA, Symmans WF, Moulder SL, Ueno NT, Lim B. Evaluation of predictive biomarkers for AR therapy and to identify the LAR subtype of TNBC. American Society of Clinical Oncology, 2019. e-Pub 2019.
98. Crespo J, Seth S, Ravenberg E, Huo L, Hess K, Santiago L, Adrada B, Rauch G, Senthil D, Murthy R, Litton J, Tripathy D, Ueno N, Moulder S, Lim B. Characterization of the LAR-subtype triple-negative breast cancer population. American Association For Cancer Research, 2019. e-Pub 2019.
99. Ueno N T, Tahara, R K, Reuben J M, Gao H, Saigal B, Fujii T, Lucci A, Ibrahim, N K, Damodaran S, Shen Y, Liu D D, Hortobagyi G N, Tripathy D, Lim B, Chasen B A. CTCs and SUV to predict the efficacy of the bone-specific radiopharmaceutical agent radium-223 dichloride combined with hormonal therapy for hormone receptor-positive bone-dominant breast cancer metastasis. San Antonio Breast Cancer Symposium, 2018. e-Pub 2018.
100. Damodaran S, Meric-Bernstam F, Hess K R, Litton J K, Hortobagyi G N, Raymond V, Lanman R, Ueno N T, Hamilton S, Wistuba I I, Valero V, Moulder S L, Tripathy D. INTERACT- INTegrated Evaluation of Resistance and Actionability using Circulating Tumor DNA in hormone receptor (HR) positive metastatic breast cancers (MBC). San Antonio Breast Cancer Symposium, 2018. e-Pub 2018.
101. Yam C, Raghavendra A, Hess K R, Adrada B, Candelaria R P, Damodaran S, Gilcrease M, Helgason T, Hortobagyi G N, Huo L, Layman R M, Lim B, Litton J K, Mittendorf E A, Murthy R K, Piwnica-Worms H, Rauch G, Santiago L, Symmans W F, Thompson A M, Tripathy D, Ueno N T, Valero V, Barcenas C H, Moulder S L, Yang W. Impact of serial biopsies in triple-negative breast cancer patients receiving neoadjuvant systemic therapy. San Antonio Breast Cancer Symposium, 2018. e-Pub 2018.
102. Yam C, Seth S, Hess KR, Mittendorf EA, Murthy RK, Damodaran S, Helgason T, Huo L, Gilcrease MZ, Chang JT, Moulder SL. Impact of clinical, morphologic and molecular characteristics on response to neoadjuvant systemic therapy (NAST) in metaplastic breast cancer (MpBC). European Society of Medical Oncology, 2018. e-Pub 2018.
103. Litton JK, Moulder SL, Damodaran S, Rauch GM, Candelaria R, Adrada BE, Symmons F, Murthy RK, Helgason T, Clayborn A, Prabhakaran S, Valero V, Thompson AM, Mitterdorf EA. Neoadjuvant trial of nab-paclitaxel and atezolizumab (Atezo), a PD-L1 inhibitor, in patients (pts) with chemo-insensitive triple negative breast cancer (TNBC). European Society of Medical Oncology, 2018. e-Pub 2018.
104. Moulder S L, Hess K R, Candelaria R P, Santiago L, Adrada B, Yang W T, Gilcrease M Z, Huo L, Stauder M C, Arun B, Layman R, Murthy R K, Damodaran S, Ueno N T, Thompson A M, Lim B, Mittendorf E A, Litton J K, Symmans W F. Precision neoadjuvant therapy (P-NAT): A planned interim analysis of a randomized, TNBC enrolling trial to confirm molecular profiling improves survival (ARTEMIS). American Society of Clinical Oncology, 2018. e-Pub 2018.
105. Yam C, Hess K R, Litton J K, Yang W T, Santiago L, Candelaria R P, Mittendorf E A, Murthy R K, Damodaran S, Helgason T, Huo L, Thompson A M, Huang M L, Arribas, E A, Lane D L, Rauch G M, Adrada B E, Gilcrease M Z, Moulder S L. Impact of metaplastic histology (MpBC) in triple-negative breast cancer (TNBC) patients (pts) receiving neoadjuvant systemic therapy (NAST). American Society of Clinical Oncology, 2018. e-Pub 2018.
106. Pairawan S S, Hess K R, Janku F, Sanchez N S, Eng C, Damodaran S, Javle M M, Kaseb A O, Hong D S, Subbiah V, Fu S, Fogelman D R, Raymond V M, Lanman R B, Meric-Bernstam F. Cell-free circulating tumor DNA somatic alteration burden and its impact on survival in metastatic cancer. American Society of Clinical Oncology, 2018. e-Pub 2018.
107. Litton J K, Scoggins M, Hess K R, Adrada B, Barcenas C H, Murthy R K, Damodaran S, DeSnyder S M, Brewster A M, Thompson A M, Ibrahim, N K, Moulder S L, Schwartz-Gomez J, Mittendorf E A, Arun B. Neoadjuvant talazoparib (TALA) for operable breast cancer patients with a BRCA mutation (BRCA+). American Society of Clinical Oncology, 2018. e-Pub 2018.
108. Ueno N T, Tahara, R K, Saigal B, Fujii T, Reuben J M, Gao H, Lucci A, Ibrahim, N K, Damodaran S, Shen Y, Liu D D, Hortobagyi G N, Tripathy D, Lim B, Chasen B A. Phase II study of Ra-223 combined with hormonal therapy and denosumab for treatment of hormone receptor-positive breast cancer with bone-dominant metastasis. American Society of Clinical Oncology, 2018. e-Pub 2018.
109. Tahara, R K, Fujii T, Saigal B, Ibrahim, N K, Damodaran S, Barcenas C H, Murray J L, Chasen B A, Shen Y, Liu D D, Hortobagyi G N, Tripathy D, Ueno N T. Phase II study of the feasibility and safety of radium-223 dichloride in combination with hormonal therapy and denosumab for the treatment of patients with hormone receptor-positive breast cancer with bone-dominant metastasis. San Antonio Breast Cancer Symposium, 2017. e-Pub 2017.
110. Yam C, Huo L, Hess K R, Litton J K, Yang W, Piwnica-Worms H, Mittendorf E A, Ueno N T, Lim B, Murthy R K, Damodaran S, Helgason T, Huo L, Thompson A M, Santiago L, Candelaria R P, Rauch G, Adrada B, Symmans W F, Gilcrease M, Moulder S L. Androgen Receptor (AR) Positivity is Associated with Nodal Disease in Triple Negative Breast Cancer (TNBC). San Antonio Breast Cancer Symposium, 2017. e-Pub 2017.
111. Yam C, Fornage, B D, Santiago L, Candelaria R P, Adrada B, Rauch G, Hess K R, Litton J K, Piwnica-Worms H, Mittendorf E A, Ueno N T, Lim B, Murthy R K, Damodaran S, Helgason T, Huo L, Thompson A M, Gilcrease M, Symmans W F, Moulder S, Yang W. Risk of Needle-Track Seeding with Serial Ultrasound Guided Biopsies in Triple Negative Breast Cancer (TNBC). San Antonio Breast Cancer Symposium, 2017. e-Pub 2017.
112. Damodaran S, Symmans F, Helgason T, Mittendorf E A, Tripathy D, Hess K, Litton J, Moulder. A Phase II Trial Of Mirvetuximab Soravtansine In Patients With Localized Triple-Negative Breast Cancer (TNBC) With Tumors Predicted Insensitive To Standard Neoadjuvant Chemotherapy (NACT) Including A Lead-In Cohort To Establish Activity In Patients With Metastatic TNBC. European Society for Medical Oncology, 2017. e-Pub 2017.
113. Yam C, Hess K R, Litton J K, Yang W T, Piwnica-Worms H, Mittendorf E A, Ueno N T, Lim B, Murthy R K, Damodaran S, Helgason T, Huo L, Thompson A M, Gilcrease M, Santiago L, Candelaria R P, Rauch G, Adrada B, Symmans W F, Moulder S L. A Randomized, Triple Negative Breast Cancer Enrolling Trial To Confirm Molecular Profiling Improves Survival (ARTEMIS). American Society of Clinical Oncology, 2017. e-Pub 2017.
114. Damodaran S, Hess K, Rauch M, Astrada B, Santiago L, Litton J, Mittendorf E, Lim B, Ueno N, Tripathy D, Thompson A, Gilcrease M, Yang W, Piwnica-Worms H, Symmans W, Moulder SL. A phase II trial of liposomal doxorubicin, bevacizumab and everolimus (DAE) in patients with localized triple-negative breast cancer (TNBC) with tumors predicted insensitive to standard neoadjuvant chemotherapy. American Association For Cancer Research, 2017. e-Pub 2017.
115. Ding Q, Chen H, Lim B, Damodaran S, Chen W, Tripathy D, Piha-Paul S, Luthra R, Broaddus RR, Meric-Bernstam F, Sahin A. Somatic Mutation Analysis in Breast Cancer: Correlation with Clinicopathologic Features. USCAP Annual Meeting, 2017. e-Pub 2017.
116. Damodaran S, Dlugos CA, Rabin RA. Effects of chronic ethanol administration in zebrafish: proteomic study using 2-D DIGE. Sigma Xi Research Day, 2006. e-Pub 2006.
117. Damodaran S, Dlugos CA, Rabin RA. Effects of chronic ethanol administration in zebrafish: proteomic study using 2-D DIGE. Eastern Atlantic Student Research Forum, 2006. e-Pub 2006.
118. Damodaran S, Rabin RA. Mechanism of tolerance to ethanol: proteomic study in zebrafish. Pharmacological Sciences Day, 2004. e-Pub 2004.
119. Vadivelu MK, Damodaran S, Solomon J, Rajaseharan A. Hospital based retrospective analysis of pediatric leukemias (acute) and lymphomas. 41ST Annual National Student Research Forum, 2000. e-Pub 2000.

Book Chapters

1. Tripathy D, Makhnoon S, Arun B, Sahin A, Kettner NM, Damodaran S, Keyomarsi K, Yang W, Hunt KK, Clemens M, Woodward WA, Mitchell MP, Layman R, Hobbs EA, Lim B, Dupuis M, Murthy R, Alhalabi O, Ibrahim N, Subbiah IS, Barcenas C. Neoplasms of the Breast. In: Holland-Freid Cancer Medicine. 10. Wiley Baker, 1361-1412, 2023.
2. Parker C, Damodaran S, Bland KI, K Hunt AK. The Breast. In: Schwartz’s Principles of Surgery. 11, 2019.
3. Damodaran S, Roychodhury S. Precision Cancer Medicine and Clinical Trial Design. In: Springer Nature. Springer Nature, 2019.
4. Damodaran S, Tripathy D. Breast Cancer. In: Handbook of Targeted Cancer Therapy and Immunotherapy, 2018.
5. Damodaran S, Berger MF, Roychowdhury S. Clinical Tumor Sequencing: Opportunities and Challenges for Precision Cancer Medicine. In: Am Soc Clin Oncol Educ Book, e175-82, 2015.
6. Damodaran S, Cataland, S R. Excessive Bleeding with Normal Prothrombin Time, Partial Thromboplastin Time, and Platelet Count. In: The Coagulation Consult–A Case-Based Guide. Springer Press, 87-97, 2014.

Books (edited and written)

1. Damodaran S, Tripathy D. Handbook of Targeted Cancer Therapy and Immunotherapy: Breast Cancer.

Web Publications

1. Newman AB, Damodaran S, Ramirez DL, Keyomarsi K, Barcenas CH. CDK4/6 Inhibitor Rechallenge in ER-Positive Breast Cancer: Understanding Which Patient Populations May Benefit.